source
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
- Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assetsEli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…